This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) two phase III studies on lebrikizumab meet the primary and all key secondary endpoints.
Exelixis (EXEL) Expands Oncology Collaboration With Invenra
by Zacks Equity Research
Exelixis (EXEL) expands collaboration with Invenra to include an additional 20 targets for multi-specific antibody, antibody-drug conjugate, and other biologic candidate discovery and development.
FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA
by Zacks Equity Research
NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.
Apellis' (APLS) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Apellis (APLS) reports a wider-than-expected loss for the second quarter of 2021. Revenues too miss expectations.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in first-quarter fiscal 2022 (ended Jun 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down
by Zacks Equity Research
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the second quarter and misses on sales.
Axsome (AXSM) Q2 Earnings Top, AXS-05 Approval Likely Delayed
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports narrower-than-expected Q2 loss. Yet, share price falls steeply after it notified of a potential delay in the approval of AXS-05 for major depressive disorder
Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss for the second quarter of 2021. Pipeline development remains in focus for the company.
bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Fall Y/Y
by Zacks Equity Research
bluebird (BLUE) reports a wider-than-expected loss in second-quarter 2021 and also misses revenue estimates. Shares down in pre-market trading as FDA places clinical hold eli-cel.
Viatris (VTRS) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Viatris (VTRS) beats on Q2 earnings and sales. The company raises annual guidance.
Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Amicus (FOLD) reports narrower-than-expected Q2 loss. The sales figure also beat estimates. Following encouraging results and positive progress with pipeline candidates, the stock rises.
Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View
by Zacks Equity Research
Exelixis (EXEL) beats on both earnings and revenues in the second quarter. Both figures increase on a year-over-year basis.
Radius (RDUS) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Radius (RDUS) reports a narrower loss but misses on sales in the second quarter. The company also lowers guidance for lead drug Tymlos.
Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.
Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up
by Zacks Equity Research
Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza. As a result, stock rises.
Aerie's(AERI) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Aerie (AERI) incurs wider-than-expected loss in the second quarter of 2021 but sales beat expectations.
Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.
Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.
Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year. It plans to start a pivotal study on SRP-9001 next month. Stock up.
Will Repligen (RGEN) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Repligen (RGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.
Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.
Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.
Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.
After Golden Cross, Repligen (RGEN)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?